Transaction by Person Discharging Managerial Responsibilities Disclosure Rule DTR 3.1.4

Regulatory News Service

26 September 2016 16:00


On 26 September 2016, the interest of Sean Bohen, a person discharging managerial responsibilities, in the ordinary shares of AstraZeneca PLC changed as detailed below.

The change in interest relates to the vesting of an award of AstraZeneca American Depositary Shares (ADSs) made in September 2015 under the AstraZeneca Restricted Share Plan.

One ordinary share equals two ADSs.

After sufficient vested shares were withheld to satisfy certain tax obligations arising on the vesting, Mr Bohen has become beneficially entitled to and has received 12,385 ADSs into a personal brokerage account.

For tax purposes, the fair market value of the shares at vest was $33.97 per ADS being the closing price on the last trading day preceding the vesting day.

The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

a)

 

Name

 

Sean Bohen

 

2

 

Reason for the notification

 

a)

 

Position/status

 

Executive Vice-President, Global Medicines Development and Chief Medical Officer

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

AstraZeneca PLC

b)

 

LEI

 

Not applicable

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

AstraZeneca PLC American Depositary Shares

 

 

 

CUSIP: 046353108

 

b)

 

Nature of the transaction

 

 

Acquisition of AstraZeneca American Depositary Shares pursuant to the vesting of an award under the AstraZeneca Restricted Share Plan

c)

 

Price(s) and volume(s)

 

 

Price(s)

 

Volume(s)

$33.97

12,385

 

 

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

Not applicable – single transaction

 

 

 

 

 

e)

 

Date of the transaction

 

26 September 2016

f)

 

Place of the transaction

 

New York

About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The Company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com    

CONTACTS

Media Enquiries

 

 

 

 

Neil Burrows

UK/Global

+44 203 749 5637

Vanessa Rhodes

UK/Global

+44 203 749 5736

Karen Birmingham

UK/Global

+44 203 749 5634

Rob Skelding

UK/Global

+44 203 749 5821

Jacob Lund

Sweden

+46 8 553 260 20

Michele Meixell

US

+1 302 885 2677

 

 

 

 

Investor Enquiries

 

 

     

UK

 

 

Thomas Kudsk Larsen

 

+44 203 749 5712

Craig Marks

Finance, Fixed Income, M&A

+44 7881 615 764

Nick Stone

Respiratory & Autoimmunity

+44 203 749 5716

Henry Wheeler

Oncology

+44 203 749 5797

Christer Gruvris

Infection & Neuroscience

+44 203 749 5711

 

 

 

 

US

 

 

Lindsey Trickett

Cardiovascular & Metabolic Diseases

+1 240 543 7970

Mitch Chan

Oncology

+1 240 477 3771

Dial / Toll-Free

 

+1 866 381 7277

 

Adrian Kemp
Company Secretary
AstraZeneca PLC

tags

  • Regulatory